Adults with weight problems who regained weight after bariatric surgical procedure noticed more practical weight reduction with GLP-1 receptor agonist remedy in contrast with different weight-loss regimens, in line with knowledge printed in Weight problems.
“There are a number of medicines which might be accepted for weight administration (phentermine, topiramate-phentermine, orlistat, bupropion-naltrexone and liraglutide); nevertheless, there are restricted knowledge to assist their use to deal with post-bariatric weight regain,” Chellse L. Gazda, MD, assistant professor within the division of inside medication at College of Texas Southwestern Medical Middle, and colleagues wrote within the examine background. “Liraglutide is a GLP-1 receptor agonist that’s accepted for managing kind 2 diabetes mellitus and weight problems. Research have proven that postprandial ranges of endogenous GLP-1 after bariatric surgical procedure could be 10 to twenty instances increased in contrast with earlier than surgical procedure.”
In a retrospective examine, Gazda and colleagues analyzed knowledge from 207 adults handled for weight regain after bariatric surgical procedure at an instructional middle from January 2014 to November 2019. Researchers in contrast the share of physique weight reduction after 3, 6, 9 and 12 months of remedy amongst adults who acquired intensive life-style modification, non-GLP-1 receptor agonist pharmacotherapy or GLP-1 receptor agonists as a part of a weight-loss program, with each pharmacotherapy teams additionally using intensive life-style modification.
Researchers discovered that the share of physique weight reduction differed by remedy kind at 3, 6 and 9 months. At 3 months, adults who acquired life-style modification, non-GLP-1 receptor agonist medicine or GLP-1 receptor agonist remedy skilled imply weight lack of 1.4%, 2.2% and 4.5%, respectively (P < .001). At 6 months, imply weight-loss proportion was 0.8% for adults who acquired life-style modification, 2.9% for individuals who acquired non-GLP-1 receptor agonist medicine and 6.7% for individuals who acquired GLP-1 receptor agonist remedy, (P < .001), and 1.6%, 5.6% and 6.9% throughout the three remedy teams, respectively, at 9 months (P = .007).
“There was a big distinction within the proportion of people reaching not less than 5% weight reduction after 3, 6 and 9 months, with most occurring within the GLP-1 receptor agonist-based weight-loss program group,” the researchers wrote.
At 12 months, the share of weight reduction was numerically however not statistically important.
In a number of regression evaluation, researchers discovered the outcomes didn’t change when stratified by bariatric surgical procedure kind, including that remedy group was the one important predictor of proportion weight change.
“Primarily based on our examine, a GLP-1 receptor agonist-based weight-loss program seems to be superior to non-GLP-1 receptor agonist-based weight-loss packages and intensive life-style modification alone for treating post-bariatric surgical procedure weight regain, no matter surgical procedure kind,” the researchers wrote. “Nonetheless, bigger potential randomized research are wanted to establish the optimum remedy methods for post-bariatric weight regain, which is a frequent problem on this rising inhabitants.”